Principal Investigator
Gerald Soff
Enrollment Status
Closed
Clinical Trial ID
Institutional Protocol #
20231020
Clinical Trial Summary
PROCLAIM: 20170770: A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy-induced Thrombocytopenia in Patients Receiving Chemotherapy for Treatment of Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer
Phase
Phase III
Funding Agency/Sponsor
Industrial
Disease
Leukemia
Contact Information
Phone Number
305-243-2647